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1. Introduction
The history of immunosuppressive drugs is linked to both the evolution of scientific under‐
standing of inflammatory diseases and the development of organ allografts. These drugs are
part of a valuable arsenal for the treatment of diseases mediated by the immune system. As
medical and public health practices have evolved, infectious processes are no longer the
primary diagnostic and therapeutic challenge posed by dermatological conditions. Emerging
in this void are cutaneous manifestations mediated by the immune system that present new
management issues and require extensive use of the group of drugs described as immuno‐
modulating agents. Psoriasis, among many other diseases in the purview of the dermatologist,
is treated with these medications. Observing the use of these medications also helps to illustrate
the evolution of dermatologic therapeutics. Some of these drugs, such as topical corticoste‐
roids, are considered the basis of the dermatological therapeutic arsenal. To use these medi‐
cations appropriately, it is important to be aware of both facts and myths concerning the action
of immunosuppressive agents and the burden of side effects. [1]
The objective of this chapter is to discuss some characteristics of modern immunomodulators
that are still useful for psoriasis treatment in the biological era. Moreover, it aims to dispel
myths that might have a negative impact on the use of such drugs by clinicians. The primary
focus is on immunomodulators that have been successfully used in the treatment of psoriasis.
As such, several aspects of psoriasis immunopathophysiology and regulatory pathways of
immune cells are explored [2]. Furthermore, it is likely that there is a considerable amount of
similarity in concepts within this class of medications, given that these mechanisms describe
immunomodulator drugs. Within this framework, the intention is to provide important insight
into how the immune system can be modulated by these drugs used to treat psoriasis in a more
traditional fashion.
© 2013 Fallen et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Clinical manifestation of psoriasis
Psoriasis is a chronic, inflammatory, multi-system disorder characterized by abnormal
epidermal differentiation and hyperproliferation thought to be related to abnormal immune
system activity. According to data from various resources, about 2-3% of the general popula‐
tion suffers from psoriasis. Accepting and extrapolating these rates globally, approximately
140 to 210 million people live with psoriasis Although psoriasis is usually benign, it is a lifelong
illness with remissions and exacerbations and is sometimes refractory to treatment. Nonethe‐
less, the majority of the cases are mild or moderate psoriasis [3]. A recent study observed 75.8%
of patients to have a psoriasis area severity index (PASI) of <20 [4]. Moreover, 17-55% of
patients experience remissions of varying lengths. Plaque-type psoriasis is the most common
form, affecting 80 – 90% of patients. Inverse, erythrodermic, pustular and guttate forms of
psoriasis have also been described. Patients present with sharply demarcated, erythematous
plaques covered by silvery white scales, most commonly on the extensor surfaces and the scalp.
The natural history is variable but is often chronic and relapsing, and patients may experience
extracutaneous manifestations commonly including nail involvement and psoriatic arthritis
in up to 20% of patients [5].
3. Psoriasis pathogenesis
In the context of a complex multifactorial genetic background, environmental stimuli, such as
bacterial antigens, act agonistically on Toll-like receptors (TLR) on the surface of keratinocytes
(KC). In psoriatic patients, this stimulus induces the production of several inflammatory
mediators by KC that are released to the adjacent underlying dermis. In this pro-inflammatory
environment, endothelial cells from small vessels start to express adhesion molecules, such as
intracellular adhesion molecule-1 (ICAM-1 or CD54), vascular cell adhesion molecule-1
(VCAM-1, or CD106), and E-selectin (CD62E). These superficial molecular modifications allow
leukocytes and lymphocytes to migrate to the dermis, attracted by inflammatory chemokines
released by KC. Macrophage inflammatory protein-3 A (MIP3A), produced by the keratino‐
cytes, binds to its receptor CCR6 on leukocyte surface, blocks the leukocyte migration, and
induces the formation of structure lymphoid tissues in the dermis. The CD11c+ plasmacytoid
dendritic cells (DC) and CD3+ T cells in the organized lymphoid tissue initiate a process of
cross communication based on cytokine production.
The activated DC (CD11c+) produces TNF-α, IL-12, IL-20 and IL-23. CD3+ T cells in response
to IL-12, initially produce IFN-γ and are considered Th1 (Phase I of the cytokine pathway).
Later in the process, the continuous activation of KC induces the presence of transforming
growth factor (TGF)-β in the field. In the presence of IL-23 and TGF-β, the IL-12 chronic
stimulated CD3+ Th1 cells evolve into Th17 CD3+ T cells (Phase II of the cytokine pathway).
Th17 cells produce IL-17 and IL-22. IL-17 and IL-22 act in synergy with IL-19, IL-20 and IL-24,
produced by IL-20-activated resident macrophages, to induce keratinocyte activation and
proliferation (Phase III of the cytokine pathway). The activated and proliferative keratinocytes
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produce other proinflammatory cytokines, which maintain the vicious inflammatory cycle of
plaque psoriasis. Among the proinflammatory cytokines is IL-8 (recently converted to CXCL8),
is related to the migration of neutrophils to the plaque in psoriasis. Growth-regulated oncogene
(GRO)-α, also known as CXCL1, predisposes tissues to further cellular proliferation. Human
beta defensin (HBD)-2, HBD-3, and LL-37 induce microbacterial destruction and the release
of further bacterial antigens to the immunological environment.
4. Immunomodulators – Basic concept of drugs used to treat psoriasis
In a homeostatic situation, the immune system interacts with many antigens without notice in
a healthy individual [6]. However, the development of a hypersensitivity response induced
by the chronic stimulation of the immune system results in the clinical manifestation of a
specific group of illnesses [7]. The lack of control of the immune response is the basis of the
clinical manifestation of these diseases. In the majority of these cases, there is an increase in
the immune response activity. Therefore, the manifestation of a hypersensitivity reaction
induces the pathogenesis of autoimmune and other inflammatory diseases [8].
The basic approach for treatment of these illnesses is manipulating the immune system to reduce
its activity. In these cases, the therapeutic goal is fine-tuning of the milieu to downgrade the
pathological response and return the immune system to a state of controlled homeostasis [9, 10].
However, the modulation of the system has to bring the balance to its normal limits without
reducing it beyond these boundaries. It can be compared to adjusting the volume and the tone of
music in an orchestra. High volume and distortions reduce the beauty of the music and can cause
discomfort. In adjusting the volume and correcting the distortions, the maestro modulates the
music, creating a pleasant sensation while still ensuring that each component remains audible.
Medications for treatment of autoimmune diseases modulate the immune system [11]. They
do not cause immunosuppression because they treat a hyper-activated system [12]. Rather,
they bring the immune system to its normal levels (Figure 1).
Bringing the immune system to its normal levels resolves the symptoms caused by the
overactive inflammatory response. Immunosuppression occurs only when the immune system
is reduced to a level below its physiological level by these drugs [13]. Therefore, the correct
use of the various immunomodulators intends to bring the patient to a controlled homeostasis
with an absence of symptoms.
4.1. Development of the actual recommendations for treatment of psoriasis
There has been considerable debate in the literature regarding the most appropriate method
to determine the initial treatment in psoriasis. The general observation of the psoriasis
guideline therapy reveals that the basic decisions are based on psoriasis intensity and its form
of clinical manifestation. Body Surface Area (BSA) and Psoriasis Area and Severity Index
(PASI) are the main criteria to decide therapeutic strategy in psoriasis.
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It is well accepted that a BSA higher than 10% and/ or a PASI higher than 10 is the limit that
determines the use of systemic medication (Figure 2) [14]. This elementary principle is found
on the balance between risk and benefits of any therapy. The use of this guideline generally
results in a ration and effective therapy for psoriatic patients; however, it is not an absolute
rule. These therapy guideline suggestions are best paired with a recommended route of
administration and should always be mediated by the good judgement of an analytical
physician.
Therapy decisions and guidelines for psoriasis treatment have historically been based on
clinical trials and empirical experience with available medications. Historical review implies
a tendency of an inverse order between pathophysiology understanding and psoriasis
treatment. The understanding of psoriasis pathophysiology was not the basis of drug treat‐
ment development in the majority of the cases. Studies in other fields, or pure empirical
Figure 2. PASI and BSA scales. The putative limit between the use of topical and systemic treatment for psoriasis are
demonstrated in both ribbons.
Figure 1. Schematic representation of immune system activity and its limits over the life-course. The blue line
shows the immune system action within the normal limits boundaries. The red line displays the hyper-activated por‐
tion of the system immune activity that creates the autoimmune disease. A. It expresses a patient with untreated auto‐
immune disease. B. It illustrates a patient treated with a successful immunomodulator (orange diamond). The
immunomodulator brings the immune system within normal immune system limits and not cause immunosuppres‐
sion.
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observation, resulted in the use of immunomodulators for psoriasis. The effective use of some
of these drugs resulted in the actual immunopathophysiology model of psoriasis, not the other
way around. For example, the etiology of psoriasis was once described as primarily and
essentially an epidermal problem, independent of immunologic phenomena [15]. The main
objective of cytotoxic drugs developed in the 20th century, such as methotrexate, was to reduce
keratinocyte proliferation. However, immunological studies on psoriatic patients identified
changes in humoral immune response as part of the overall problem but not the cause [16,
17]. The efficacy of cytotoxic drugs in the late 1960s paved the road for ideas about the role of
the immune system in psoriasis [18, 19]. Further investigations in the 1970s revealed the role
of immunologic factors in psoriasis. Here, these historical developments will be used as a
context for the most recent guidelines in treatment of psoriasis.
4.2. Classification of the immunomodulators
To understand the drugs used in the treatment of psoriasis, the novice interested in this subject
ought to know how these mediations are classified. Drugs that modulate the immune system
can be classified as modifiers of the immune response to a specific antigen or antigens,
nonspecific modulators, and agents that affect the inflammatory response. They can also be
used in topical and systemic forms.
Antigen specific immune modifiers affect different stages of immune response. An example
of this process is the use of anti-Rh antibodies. The desensitization to allergen is another
example of antigen-specific immunosuppression.
Drugs such as cyclophosphamide, azathioprine, methotrexate and chlorambucil are the
prototype of nonspecific antigen modulators. These drugs derive their immunomodulatory
function primarily through cytotoxicity to immune effector cells. They are used in the treat‐
ment of both autoimmune and neoplastic diseases as well as in the control of rejection after
organ and tissue transplantation. The medical field of transplantation has increased the use
and development of these drugs. Another group of non antigen specific modulators inhibit
the stimulation of T lymphocytes. They do so by inhibiting the T lymphocyte activation
medicated by IL-2 and IL-2 receptors. Consequently, by inhibiting the activation of T lym‐
phocytes these drugs reduce immune system activity. They include cyclosporine, tacrolimus,
pimecrolimus and rapamycin.
Immunomudulators are also inhibitors of inflammatory response. Inflammation is the major
manifestation of hyper-activation of the immune system. Thus, drugs that suppress the
inflammatory response, such as NSAIDs and corticosteroids, can be useful in some circum‐
stances.
5. Topical immunomodulators used in psoriasis
There continues to be significant evolution in psoriasis therapy in recent years. However, it is
not surprising that topical forms of therapy are more prescribed than systemic forms in the
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treatment of psoriasis. Although psoriasis is usually benign, it is a lifelong illness with
remissions and exacerbations and is sometimes refractory to treatment. Nonetheless, the
majority of the cases of psoriasis are mild or moderate in severity [3] and can be effectively
treated with topical immunomodulators. Some studies suggest that approximately 10% of
patients with psoriasis progress to develop psoriatic arthritis. The systemic therapies are used
in severe forms of psoriasis.
Topical therapy for psoriasis is used as the first form of treatment. The main objective of the
therapy is to achieve short-term suppression of symptoms, and long-term modulation of
disease severity. Moreover, topical therapy intends to improve quality of life with minimal
adverse effects; however, there is no clear guidelines regarding the topical agent to be used in
each type of psoriasis Therefore, the topical medications will be presented here on the basis of
their historical evolution (Figure 3). There are some basic rules, which practitioners can apply
in assessing when psoriasis can be managed with topical agents alone'. For example, patients
with limited disease (usually < 10% of their body surface) can often be managed topically. For
plaques, medium- to high-potency corticosteroids used daily is commonly the first choice of
therapy. Coal tar preparations can be best used along with topical corticosteroids in rotation.
Anthralin is more commonly used in short- term management of chronic plaque psoriasis.
Vitamin D3 analogs are an effective treatment for mild to moderately severe plaque psoriasis
and are well tolerated on the face and intertriginous areas without the use of corticosteroids.
5.1. Emollients
Emollient creams and lotions were developed because they are helpful in controlling scales
and relieving pruritus. Emollients containing ingredients such as mineral oil are particularly
helpful at relieving the dryness experienced with psoriasis. Emollients fill cavities and fissures
of the skin with fat resulting in moisture retention and soft skin [20].
5.1.1. Emollients: Evidence summary for psoriasis treatment
They are available as over-the-counter preparations and should be applied at least once a day,
preferably twice a day, but can be applied more often if required. Although both preparations
are effective, most patients prefer creams to ointments, and compliance tends to be better with
cream preparations.
5.2. Coal tar
Coal Tar was one of the first topical immunomodulators used for psoriasis treatment. One of
the earliest references to its use was by the British Hospital for Diseases of the Skin in 1884. [21]
Coal tar preparations can be effective for long-term management of psoriasis, with less side
effects and rebound upon cessation than topical steroids. However, the exact mechanism of
action of coal tar is not completely understood. The possible mechanism of action is the
reduction of mitotic rate in the epidermis. This results in keratoplastic and anti-acanthotic
properties. It can have an atrophogenic effect on the human epidermis. Finally, it has a
photosensitizing effect with an absorption spectrum of 330–550 nm. This last effect is greatly
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enhanced by irradiation of the treated skin with UVA but not with UVB or UVC [22]. It seems
that coal tar does not have a specific effect on the immune system of the skin [23].
When crude coal tar is refined or separate in different extracts, the result compound is called
brown tar or liquor carbonis detergens (LCD). It is available in many different formulas such
as soaks and shampoos. LCD is less effective than coal tar when combined with UVB for
psoriasis therapy [24].
5.2.1. Coal tar: Evidence summary for psoriasis treatment
Tar preparations were once a popular treatment for psoriasis but have largely been replaced
by topical corticosteroids due to the fact that these preparations are messy to use, can stain
clothes, and have an unpleasant odor. They are effective in treating mild to moderate psoriasis
[25].
5.3. Anthralin
Anthralin was developed from an herbal medication called Goa powder made from the bark
of the South American araroba tree. Anthralin can be compounded in various vehicles and
strengths, from 0.1% up to 10% or higher when specially compounded. It is usually necessary
to add 3 to 10% salicylic acid in the formulation, not only as a keratolytic but also as a preser‐
vative to retard the oxidation of anthralin. Anthralin also causes a brown–red discoloration of
the skin [26].
It is moderately effective and quite safe in plaque psoriasis. As for the main mechanism of
action in psoriasis, anthralin is known to have antimitotic activity. The major side effect is
occasional irritation. Use on acute, exudative, inflamed psoriatic plaques should be prevented.
Irritation is more likely to occur in the perilesional skin than on the psoriasis plaque. Short
contact treatment is used to reduce irritation but application for 8–12 hours is more effective
[27]. The combination of the anthralin compound and UVB phototherapy is known as the
Ingram regimen [28].
Figure 3. Google Books Ngram Viewer for old topical therapy for psoriasis. It displays a time line of how often the
word Emollient, Coal tar, Liquor Carbonis Detergens, and Anthralin have occurred in a corpus of books written in Eng‐
lish between 1800 and 1960. It roughly indicates the time of these therapies introduction in medicine.
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5.3.1. Anthralin: Evidence summary for psoriasis treatment
Anthralin used to be a mainstay for the topical treatment of psoriasis in the inpatient setting.
However, its use has declined because of the availability of alternatives. It has been reported
to be successful in treating mild to moderate psoriasis. When using Anthralin, it is best to start
at the lowest strength and increase gradually as required according to response. Adverse
effects include severe skin irritation, staining of clothing, and unpleasant smell.
5.4. Topical steroids
Topical steroids are the most used medication in the treatment of psoriasis. Corticosteroids
were discovered in 1935 as compound E or cortisone [29]. The first therapeutic uses were in
the treatment of rheumatoid arthritis and rheumatic fever followed by the treatment of
inflammatory skin disease [30]. The topical use of steroids originated in 1952 as compound F
or hydrocortisone [31]. Finally, psoriasis was included in the list of skin diseases treatable with
hydrocortisone in 1955 [32].
The next step in the development of topical steroids included numerous modifications of
the molecule and improvements in delivery systems of  the drugs to increase their  anti-
inflammatory activity.  Application of a thin film to psoriatic plaques two to three times
daily  is  the  basic  instruction  of  topical  steroids  usage.  Topical  steroids  have  different
potencies  based  on  their  formulations  [33].  The  efficacy  is  directly  related  to  the  skin
penetration of  steroid molecules  and the rate  of  absorption is  influenced by the steroid
chemical structure. Other factors such as formulation vehicle and status of the skin also play
a role in the absorption of the medication [34, 35].
It is not an easy decision to prescribe topical steroid for psoriasis. Among many other factors,
anatomical site, amount, frequency of application should be considered too' [36]. For example,
no topical corticosteroids should be used on the face, axilla, or groin, other than low-potency
ones, unless otherwise recommended by the doctor. These concerns are related to the action
of corticosteroids on the epidermis, which is to reduce the epidermis’ ability to proliferate by
interfering with RNA synthesis. Steroid antimitotic effect in cutaneous psoriasis demonstrates
that the therapeutic effects are under the stratum corneum [33, 37].
Steroid antimitotic effects on the skin can cause a thinning of the epidermis. This can occur
within 7 days of use of high dose topical steroids. All layers of the epidermis are reduced
in thickness by 3 weeks of strong topical steroid use. The thinning of the epidermis impairs
physiological  functions  of  the  epidermis  and  may  be  associated  with  the  rebound  of
inflammation, which is a paradoxical effect. Thus, potent topical glucocorticosteroids will
cause anti-inflammatory effects when first applied but with subsequent applications their
therapeutic action rapidly diminishes, which is known as tachyphylaxis [38]. However, after
a rest period of a few days, the same initial beneficial response may be produced again, but
this will also disappear if the steroid is again continued topically. Therefore, steroids should
be used for 2 to 3 weeks and then tapered with the intention of discontinuing the use of
the steroid cream [39].
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Effect of topical steroid action is not limited to the epidermis as they are able to penetrate the
stratum corneum and are absorbed into both the epidermis and the dermis. Reduction of
dermis volume occurs within 1-3 weeks of using high dose topical steroids. This acute effect
also results from interference of RNA synthesis in fibroblasts' [40]. These cells do not produce
primarily hyaluronic acid, which decreases dermal water content. However, the chronic use
causes abnormal synthesis of collagen and elastin that is the cause of dermal atrophy and
impaired wound healing [41, 42].
The steroid molecules are also absorbed to some degree into circulation when they reach the
dermis. The absorption in large areas of skin after chronic use may be sufficient to cause
systemic effects such as adrenocortical suppression. Therefore, systemic side effects have
become a very real concern with the use potent topical steroids [43]. This is one of the most
important criteria for use of BSA or PASI 10 to initiate systemic medication. Although it is rare
to see clinical systemic effects in an adult patient, there have been reported cases of hypo‐
thalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, cataracts, and
glaucoma. Moreover, children are more at risk for systemic side effects because they have
greater body mass to body surface ratio than adults. In general, high dose super potent topical
steroids are not recommended for children under age 12 because they can cause growth
retardation and failure to thrive [44, 45].
As immunomodulators, steroids initiate their mechanisms of action by binding to intracellular
receptors, and inhibits protein synthesis resulting in immunosuppression. The majority of
these events occur at the dermis. Steroids effect cell trafficking since they reduce the expression
of adhesion molecules on the vascular endothelium. Corticosteroids also have functional
effects. They alter the release of neutrophil lysosomal enzymes, decrease production of IL-1
by monocytes, induce reduction of IL-2 by T lymphocytes, and interfere with macrophage
antigen presentation. Corticosteroids reduce the binding of immunoglobulin Fc and C3b
receptors. They block lymphocyte proliferation and reduce delayed hypersensitivity respons‐
es. Many other effects are observed with corticosteroids, but these are considered to be the
most important [44, 46].
5.4.1. Topical steroids: Evidence summary for psoriasis treatment
One systematic review of topical corticosteroid preparations versus placebo for psoriasis
clearly indicated that all corticosteroids performed better than placebo. The same study
showed that potent corticosteroids had smaller benefits than very potent corticosteroids [47].
Therefore, with this in mind, pharmacological treatment of psoriasis should begin with the
use of topical corticosteroids. They are easy to apply and suitable for combination with other
therapies where monotherapy is insufficient. Generally, the lowest potency of topical cortico‐
steroid should be used. Low-potency treatments are appropriate for lesions on the face or
intertriginous areas or for infants. Adults mainly respond to a mid-potency agent. High-
potency topical corticosteroids are usually reserved for adults requiring short-term treatment
of thick plaques that are resistant to lower-potency agents [48].
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5.5. Analogues of vitamin D3 for psoriasis
Calcipotriol, calcitriol and tacalcitol are analogues of vitamin D3. Calcitriol is the naturally
occurring active form of vitamin D3. Keratinocytes possess receptors for 1,25-dihydroxyvita‐
min D. All vitamin D3 derivatives inhibit cell proliferation and stimulate differentiation of
keratinocytes. These observations inspired the use of analogues of vitamin D3 for the treatment
of psoriasis [49]. Vitamin D derivatives are more effective at improving psoriasis severity
scores at 3 to 8 weeks when compared with placebo. However, the overall data has moderate-
quality evidence [50].
Indicated for mild to moderately severe plaque psoriasis, there are more effects on the skin
than simply the enhancement of epithelial cell differentiation. Calcitriol can modulate the
skin’s immune system through interfering with antigen presenting cells, regulatory T cell
activation, cutaneous cytokine patterns, and adaptive immunity [52]. The final result is that
vitamin D3 analogues effect inflammatory cell infiltration. Interestingly, like topical cortico‐
steroids, tachyphylaxis can occur after a few weeks of use Vitamin D3 analogues. Therefore,
rotational is a useful strategy to ensure maximum therapeutic benefit. This involves rotating
vitamin D with other treatments every few weeks. Moreover, there is considerable evidence
to suggest that the hyperproliferation and inflammatory components of the disease can be
more rapidly controlled using mixtures of drugs such as the vitamin D3 analog calcipotriol
and the steroid betamethasone dipropionate [53].
5.5.1. Analogues of vitamin D3: Evidence summary for psoriasis treatment
Vitamin D3 analogues have the advantage of being cosmetically more acceptable to patients
than coal tar or anthralin preparations, but they may cause irritant dermatitis and photosen‐
sitivity in some patients. Calcitriol can be used on the scalp and flexural areas. Cream formu‐
lation may be well tolerated on the face and intertriginous areas. They should be avoided in
generalised pustular erythrodermic exfoliative psoriasis and individuals with calcium
metabolism disorders. Patients are limited to a maximum of 100 g/week because there is a
potential risk of hypercalcemia and hypercalciuria, although this occurrence is rare.
5.6. Tazarotene
The use of oral retinoids for psoriasis treatment precedes that of their use topically. However,
the success of these oral therapies, and the development of topical retinoids for other derma‐
toses, triggered the development of tazarotene. Tazarotene is a selective topical retinoid for
psoriasis treatment. Efficacy and safety of this agent has been established as a monotherapy
or in combination with other therapies, particularly topical corticosteroids and phototherapy
[54, 55].
Like other retinoid derivatives, tazarotene binds the retinoic acid receptor (RAR) but in a class-
specific manner. It preferentially binds to RAR-γ and RAR-β over RAR-α and it does not bind
retinoid X receptor (RXR) [56]. As a result of the binding at the RAR receptor, tazarotene seems
to cause a reduction in proliferation and normalizes the differentiation of keratinocytes [57]. It
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also possesses indirect  anti-inflammatory properties  by affecting keratinocyte chemokine
production which reduces the dermal infiltration [58].
Tazarotene may be effective in the short term at improving symptoms of mild to moderate
chronic plaque psoriasis [59]. It may cause skin irritation, including burning, stinging and itch
in up to 30% of users [60]. It is potentially teratogenic and is contraindicated in women who
may be/become pregnant [61, 62].
5.6.1. Tazarotene: Evidence summary for psoriasis treatment
Tazarotene may be effective as a short term therapy of mild to moderate chronic plaque
psoriasis. It may cause skin irritation, including burning, stinging and itch in up to 30% of
users. It is potentially teratogenic and is contraindicated pregnant or would be pregnant
women'
5.7. Topical calcineurin inhibitors
Calcineurin inhibitors (CIs), such as tacrolimus and pimecrolimus, are large lipophilic
molecules that may be used topically in the treatment of psoriasis [63]. Their lipophilicity and
size keep them in the skin with minimal systemic absorption [64, 65]. The main advantage of
these drugs is the possibility of maintenance therapy for long periods eliminating the need for
prolonged corticosteroids and their side effects [66].
Tacrolimus and pimecrolimus interact intracellularly by inhibiting the protein NFAT activa‐
tion (Nuclear Factor Activating T cell) by calcineurin [67]. This works by blocking T lympho‐
cyte mediated signaling and cytokine production. Topical CIs prevent transcription of
inflammatory cytokines, including interleukin (IL)-2, IL-3, IL-4, IL-5, interferon (IFN)-γ and
tumor necrosis factor (TNF)-α, which normally contribute to psoriatic lesions [68]. Downre‐
gulation of the high-affinity IgE receptor on Langerhans cells and inhibition of the release of
inflammatory mediators from mast cells and basophils may also partly explain the effect of
CIs when used topically [69]. Finally, recent evidence suggests that topical CIs may not act
primarily by inhibiting the calcineurin/NFAT axis in lymphocytes in the skin but rather that
they may instead act by decreasing NFAT2 activity in follicular keratinocytes [70]. These
characteristics further support the topical use of CIs in the treatment of psoriasis.
Currently, calcineurin inhibitors are approved for atopic dermatitis (AD) treatment only.
Despite their efficacy in AD management, CIs are ineffective in non-intertriginous psoriatic
plaques management. This lack of efficacy is credited to the inability of CIs to penetrate the
thick psoriatic plaques, however, they may be effective when used under occlusion on descaled
small plaques. Tacrolimus therapy is more effective in the treatment of the face and intertri‐
ginous areas and is particularly useful because it does not cause skin atrophy or changes in
collagen synthesis [71].
Most studies about the safety of CIs are centered on patients with atopic dermatitis. However,
these products continue to be used off-label for psoriasis. Topical adverse effects of CIs may
actually occur less frequently on the thick plaques of psoriasis. Both topical tacrolimus and
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pimecrolimus may cause a stinging or burning sensation. Occasionally, patients using CIs
experience flu-like symptoms, headaches, folliculitis and increased flushing after alcohol use.
The FDA has raised concerns about the safety of CIs and has issued a black-box warning
regarding the use of both tacrolimus and pimecrolimus. This concern is based on evidence of
malignancy after long-term use of oral CIs and is not related to topical use. However, the FDA
did not confirm a casual relationship between the use of CIs and the cases of malignancy.
Further investigations regarding the safety of topical immunomodulators did not confirm the
FDAs concerns. Furthermore, clinical evidence up to this point has not shown an enhanced
risk of cancer after the use of either topical tacrolimus or pimecrolimus.
5.7.1. Calcineurin inhibitors: Evidence summary for psoriasis treatment
Calcineurin inhibitors have moderate efficacy for facial and inverse or intertriginous psoriasis.
Their main indications are facial or inverse psoriasis that have not been responsive to weak or
moderate strength topical steroids.
6. Summary of topical medications used in psoriasis treatment
Treatment of psoriasis depends on the type and severity of the disease. Typically, topical
therapies are used to treat mild and localized psoriasis. Topical treatments are the foundation
for mild to moderate psoriasis. However, this approach can decrease the number and thickness
of the plaque lesions, and reduce the percentage of body surface involved. In general, phar‐
macological treatment should start with the use of topical corticosteroids [72].
The complete clearance of lesions is often not a realistic goal with topical therapy but eventual‐
ly remission can be reached. Frustration related to medication efficacy expectations, poor
cosmetic characteristics of topical preparations, time consumption, fear of side effects, and
inconvenience were found to be the most important reasons patients chose to deviate from
provider recommendations of topical therapy [73]. Studies suggest that adherence with topical
treatment in psoriasis is poor. Research has shown that only 50% of topical agent applications
prescribed by physicians are actually used [74].
Patients with chronic psoriasis may be candidates for topical therapy depending on their
baseline severity. Topical treatments include creams, ointments, and lotions. The choice of
formulation depends on the area affected. Physicians should also select formulations that will
be acceptable to the patient [75]. There is a consensus that topical emollients and salicylic acid
are effective as initial and adjunctive therapy for people with chronic plaque psoriasis, but it
is unclear whether tars are effective [76].
6.1. Routine suggestions for classical mild and moderate plaque psoriasis
Topical high-potency corticosteroids may be used as first-line therapies for patients with mild
plaque psoriasis. Low-potency treatments are appropriate for infants. Other appropriate first-
line options include topical calcipotriol and calcipotriol/betamethasone dipropionate in
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combination. Non-medicinal emollients, including creams, ointments, and lotions should be
used in combination with the above agents to potentiate their effects and to help restore the
natural barrier of the skin. For appropriate patients, tazarotene may be used, either alone or
in combination with topical corticosteroids. Patients requiring ongoing treatment with topical
agents containing high-potency corticosteroids should be monitored regularly for adverse
effects and steroid-sparing concomitant treatments should be introduced. The rotation of a
nonsteroidal topical agent following initial treatment is indicated.
6.2. Routine suggestions for facial, flexural, or genital areas
Topical treatment with calcineurin inhibitors (0.1% tacrolimus ointment or 1% pimecrolimus
cream) should be used. Topical corticosteroids such as 0.1% betamethasone may be used on
an occasional or intermittent basis. Mild- or moderate-potency corticosteroids may also be
used on an occasional or intermittent basis to treat facial and genital psoriasis. In moderate to
severe facial, flexural, and genital disease, stronger corticosteroids may be applied to address
nonresponsive psoriasis or acute flares in these areas.
6.3. Routine suggestions for scalp psoriasis
Topical corticosteroids and calcipotriol are all appropriate topical treatments. Betamethasone
dipropionate lotion, clobetasol propionate solution, betamethasone valerate solution, or
calcipotriol solution are also possibilities. Calcipotriol/betamethasone dipropionate combina‐
tion gel is a recently emerging therapy.
6.4. Routine suggestions for palmar-–plantar disease
For mild and moderate manifestations, potent corticosteroid or vitamin D analogues with
salicylic acid preparations should be used. For intense forms, high-potency corticosteroids
with salicylic acid and urea preparations are the main choice of therapy.
7. Conclusion
The treatment of diseases involving the immune system has progressed in recent years with
the introduction of new immunomodulators in clinical practice. These drugs act at different
points in the immune response and may significantly alter the immune response of the patient,
especially if combined. However, topical therapies continue to serve as the fundamental basis
for any physician when dealing with psoriasis. Understanding the mechanism of action of
these drugs is necessary for better management and proper application in situations where
clinical challenges appear. Further research and development in the field of topical immuno‐
modulators will hopefully result in the design of even more effective drugs, with increased
specificity of action and fewer side effects.
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